Palatin Technologies Says USPTO Issues Patent On Vyleesi For Hypoactive Sexual Desire Disorder
(RTTNews) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Tuesday that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension."
This issued patent further strengthens the Company's intellectual property position and coverage for the Company's approved therapeutic product for hypoactive sexual desire disorder in premenopausal women, Vyleesi.
The patent has, with patent terms adjustments, a term through April 29, 2041. The claims of the patent relate to use of bremelanotide, marketed by the Company under the trade name Vyleesi, for treatment of female sexual dysfunction in patients with controlled hypertension. The patent is solely owned by the Company.
Palatin Technologies Completes Sale Of Vyleesi To Cosette Pharma For Up To $171 Mln
European Shares Drift Lower Ahead Of US Inflation Reading
Antipodean Currencies Rise As Traders Await U.S. PCE Inflation Data
Asian Shares Mixed Ahead Of US PCE Inflation Data
NZ Dollar Advances Against Majors
Australian Dollar Rises Against Majors
European Shares Seen Mostly Lower Before US Inflation Data
